Drugs / ONC206
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04732065 | Aug 2021 → May 2027 expected | ependymoma, glioblastoma, grade III glioma, spinal cord glioma | Sabine Mueller, MD, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT04541082 | Oct 2020 → Jul 2026 overdue | anaplastic astrocytoma, anaplastic ependymoma, anaplastic meningioma, anaplastic oligodendroglioma +14 | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07282587 | Jan 2026 → Dec 2028 expected | pheochromocytoma-paraganglioma | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONC206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07282587 ↗ |
| Known as | JZP3507 | “Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma” NCT07282587 ↗ |
| Action | Activate | “activation of the mitochondrial ClpP protease by mutant ClpP (Y118A) or through utilization of second-generation imipridone compounds (ONC206 and ONC212)” PMID 35417530 ↗ May 2022 |
| Modality | Small molecule | “ONC206 is a member of the imipridone class of anti-cancer small molecules” NCT04541082 ↗ |
| Route | Oral | “single-agent, oral ONC206” NCT04541082 ↗ |
| Target | CLPP | “activation of the mitochondrial ClpP protease by mutant ClpP (Y118A) or through utilization of second-generation imipridone compounds (ONC206 and ONC212)” PMID 35417530 ↗ May 2022 |